First pediatric institution in U.S. to offer magnetic navigation technology for cardiac ablation

 

ST. LOUIS, July 08, 2016 -- Stereotaxis, Inc. (STXS), a global leader in innovative technologies for the treatment of cardiac arrhythmias, today announced that Texas Children’s Hospital in Houston has installed the Company’s Niobe® ES system, making it the only pediatric hospital in the country to offer the latest generation remote magnetic navigation platform for ablation procedures. Texas Children’s is recognized as one of the top children’s hospitals in the nation, ranked #2 nationally in cardiology and heart surgery by U.S. News & World Report.

 

“We are privileged to provide this cutting-edge treatment for our patients with arrhythmias in whom cardiac ablations are deemed necessary,” said Dr. Jeffrey Kim, director of the Arrhythmia and Pacing Service at Texas Children’s. “With the Niobesystem, we can more quickly and aggressively target and ablate abnormal electrical impulses in young children and patients with structurally complex anatomy. This is an important tool in our armamentarium for this highly specialized procedure and undoubtedly advances our approach to pediatric cardiac rhythm management.”

BEIJING, China, July 7, 2016 -- Dehaier Medical Systems Ltd. (DHRM) ("Dehaier" or the "Company"), which develops, markets and sells medical devices and wearable sleep respiratory products in China, announced on July 5, 2016 that it is partnering with China Sciences Group (Holding) Co., Ltd. ("China Sciences") to enter the Chinese pension and health industry by providing Dehaier's products through China Sciences' elder care platform. In connection with this announcement, Dehaier, China Sciences and another supplier, Chia Tai Pharmaceutical Group ("Chia Tai"), have signed a strategic cooperation agreement to launch the "Elderly Sleep Apnea Comprehensive Disease Solution Project" (the "Project"). The Project will leverage China Sciences' "Hui Kang" cloud-based health management platform to provide Dehaier's and Chia Tai's medical devices to the elderly.

 

China Sciences is a state-owned enterprise, organized under the auspices of the Chinese Academy of Sciences ("CAS"). With total assets of nearly RMB 10 billion, China Sciences' health pension model enjoys brand and research support from CAS. The Hui Kang "Internet + Medical Support" business model will benefit users of Dehaier's smart wearables with a large, well-received platform. Hui Kang integrates a variety of localized health and pension service organizations and has grown to cover more than 300 cities in more than 20 provinces and serve nearly one million members since the start of October 2014. The Project is expected to reach approximately 100 health and pension service institutions in 2016, and 600 in 2017.

NEWTOWN, PENNSYLVANIA--(Jul 5, 2016) - Helius Medical Technologies, Inc. (HSM.TO)(HSDT) ("Helius" or the "Company") is pleased to announce that the results from the Multiple Sclerosis (MS) Pilot Study, investigating PoNS™ Therapy, will be presented in London on July 6th, during the mid-year meeting for the International Neuropsychological Society (INS). The independent study took place at the Montreal Neurological Institute and Hospital and Concordia University's PERFORM Center.

 

The poster, "Non-Invasive, neuromodulation combined with intensive cognitive and physical rehabilitation induces neuroplastic changes in patients with multiple sclerosis (MS)" will be presented by Dr. Gabriel Leonard, and will detail the results of PoNS™ Therapy in the 14-subject, controlled MS pilot study for which top-line results were released on Nov 2, 2015. At that time, it was announced that the active PoNS™ Therapy contributes to neuroplastic change (as measured with fMRI) and is associated with improved performance when compared to the control group.

Double and Multiple-Channel Endoscopes (with No More than Four Channels) Among Devices Cleared for Use in TSO3's STERIZONE® VP4 Sterilizer – an Industry First

 

QUÉBEC CITY, July 4, 2016  - TSO3 Inc. (TSX:TOS.TO - News), an innovator in sterilization technology for medical devices in healthcare settings, announced today that theU.S. Food and Drug Administration ("FDA" or "Agency") has cleared TSO3's expanded indications for use (IFU's) of itsSTERIZONE® VP4 Sterilizer.

 

Regulatory clearance of the additional claims represents an entirely new level of patient protection against ineffective device reprocessing resulting from the use of less robust disinfecting systems, particularly for flexible endoscopes.